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Background: The lungworm Dictyocaulus viviparus, causing parasitic bronchitis in cattle, induces a temporary
protective immunity that prevents clinical disease. A radiation-attenuated larvae based vaccine is commercially
available in a few European countries, but has the disadvantages of a live vaccine. As a recombinant subunit
vaccine would overcome these disadvantages, the parasite’s muscle protein paramyosin (PMY) was tested as a
recombinant vaccine antigen.
Methods: D. viviparus-PMY was recombinantly expressed in Escherichia coli as a glutathione-S-transferase
(GST)-fused protein. Emulsified in adjuvant Saponin Quil A, the protein was given intramuscularly into calves.
Two independent recombinant PMY (rPMY) vaccination trials with negative control groups (first trial: adjuvant
only; second trial: non-fused GST) as well as an additional positive control group in the second trial, using the
Bovilis©Dictol live vaccine to verify vaccination results, were performed. To determine the vaccination success,
shedding of larvae as well as worm burden and worm sizes were analyzed. Additionally, ELISA-based determination of
development of immunglobulins IgM, IgA, IgE, IgG as well as the subclasses IgG1 and IgG2 was performed. To analyze
PMY localization in the bovine lungworm, immunohistochemical staining of adult worms was carried out.
Results: Immunohistochemical staining revealed that PMY is part of the bovine lungworm’s pharyngeal and body wall
muscles. Vaccination with rPMY resulted in 47% [geometric mean: 67%] and 57% (geometric mean: 71%) reduction of
larvae shedding in the first and second vaccination trial, respectively. Worm burden was reduced by 54% (geometric
mean: 86%) and 31% (geometric mean: 68%), respectively, and worms of rPMY-vaccinated cattle were significantly
shorter in both trials. Furthermore, ELISAs showed a clear antibody response towards rPMY with exception of IgE for
which titers could not be detected. After challenge infection, rPMY antibodies were only exceptionally elevated among
study animals indicating PMY to be a hidden antigen.
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Conclusions: Even though vaccination with the attenuated live vaccine was with 94% (geometric mean: 95%)
reduction in larvae shedding and 93% (geometric mean: 94%) reduction in worm burden superior to rPMY vaccination,
results using the latter are promising and show the potential for further development of a recombinant PMY-based
vaccine against the bovine lungworm.
Keywords: Dictyocaulus viviparus, Bovine lungworm, Parasitic bronchitis, Recombinant vaccine, Vaccination,
Immunization, Paramyosin, Hidden antigenBackground
Dictyocaulosis in cattle, also known as parasitic bron-
chitis, is caused by the bovine lungworm Dictyocaulus
viviparus. Cattle surviving the infection develop protect-
ive immunity lasting for up to one year. Based on the
principle of induced protective immunological reactions,
a live vaccine composed of irradiated third stage larvae
(L3) was developed in the sixties of the last century by
Jarrett et al. [1]. However, due to its high costs, limited
shelf life and for ethical reasons, acceptance among veteri-
narians and farmers decreases nowadays. Therefore, control
of the parasite relies primarily on anthelmintic treatment
and pasture management.
The present study aimed to evaluate the potential of the
antigen paramyosin as a recombinant subunit vaccine
against the bovine lungworm in clinical vaccine trials. The
muscle protein paramyosin (PMY) was firstly identified as
a structural component of invertebrate muscle cells and is
currently considered to be a significant part of the body
wall and pharyngeal muscles of helminths [2-4]. PMY is
usually associated with myosin and the core proteins and
forms the macromolecular thick filaments [5,6]. Generally,
its molecular weight is about 100 kDa and it is charac-
terized by a two-chain alpha-helical coiled-coil structure
[7]. Studies on various platyhelminths showed that PMY
has the ability to bind collagen and interact with parts of
the complement system, assumedly by binding to the
collagen-like stalk regions of the complement subcompo-
nent C1q [8,9]. Additionally, Taenia crassiceps-PMY was
awarded the ability to bind the Fc part of antibodies [10].
Thus, a secreted or non-filamentous and surface-bound
form of PMY may mask the worm against the host im-
mune system [11]. Regarding nematodes, Zhang et al. [12]
found that the outer membrane form of Trichinella spira-
lis-PMY plays an important role in the evasion of the host
complement attack: Recombinantly expressed T. spiralis-
PMY strongly bound to complement components C8 and
C9 and inhibited the polymerization of C9 during the
formation of the membrane attack complex. Strube et al.
[13] demonstrated that recombinant PMY (rPMY) of
D. viviparus was able to bind bovine IgG as well as bo-
vine collagen. Thus, bovine lungworm-PMY might also
have immunomodulatory functions protecting against host
defense mechanisms, making it a potential vaccine targetto control parasitic bronchitis. This assumption is substan-
tiated by promising rPMY vaccination trials against trema-
todes like Schistosoma spp. and Fasciola gigantica [14-16].
In these studies, performed in the murine model and rab-
bits, respectively, rPMY vaccination led to an increase of
specific antibody-titers in serum samples of vaccinated an-
imals. Vaccination trials in large animal hosts like cattle,
sheep or pigs with recombinant S. japonicum-PMY re-
sulted in a partial protection against challenge infections:
After immunization of pigs, 32-35% reduction of worm
burden was observed [17]. When using the 3’ fragment of
S. japonicum-PMY in the ovine host [18], 37% and 42%
reduction of egg counts and 30% reduction of worms was
reached, whereas native PMY obtained higher protection
with 63% reduction of egg counts and 48% reduction of
worms. McManus et al. [19] used full length rPMY of
S. japonicum in combination with the adjuvant Quil A to
vaccinate water buffaloes and achieved 49% reduction
of egg counts and 34% reduction of worm burden. In
nematodes, immunization with plasmid DNA encoding
the Brugia malayi-PMY (BM5) induced development of
strong antibody responses in mice [20,21]; however, vac-
cination of jirds did not result in reduced worm burdens
[20]. Vaccination of BALB/c mice with recombinantly
expressed T. spiralis-PMY achieved 36.2% reduction in
muscle larvae burden following challenge infection [22].
The above results suggest PMY as a valuable helminth
vaccine candidate why its protective potential against




D. viviparus-PMY was recombinantly expressed in One
Shot® BL21 Star™ (DE3) chemically competent E. coli (Life
Technologies, Germany) as a glutathione-S-tranferase
(GST)-fused protein using the expression vector pET-41a
(Merck Millipore, Germany). After purification as previ-
ously described by Strube et al. [13], rPMY was stored
at −80°C in sterile 50 mM Tris buffer (pH 8.0) until use.
Animals and immunization
In a first vaccination trial, ten parasite-naïve, male
Holstein-Friesian calves, six to seven months of age (body
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group consisting of four cattle and a control group (adju-
vant only-control) consisting of 6 cattle. In a second vac-
cination trial, 18 parasite-naïve, five to seven months old
calves [Holstein-Friesian breed except one Simmental
breed (Animal-ID: 553); bodyweight 139 to 182 kg]
were randomized into a vaccine group, and two control
groups [solely vaccinated with the vector-GST-tag (GST-
control) or the commercially available live vaccine (Dictol
group), respectively] of six animals each. Animal experi-
ments were permitted by the ethics commission of the
Lower Saxony State Office for Consumer Protection and
Food Safety under reference number AZ509.6-42502-04/
853. The second vaccination study was run under permit
number D25A_05 of the Veterinary Authorities of the
Canton of Fribourg in Switzerland.
In both vaccination trials, following an acclimatization
period of seven days, cattle were immunized intramuscu-
larly in the neck on study day 0, 21 and 42. The vaccine
group of the first trial received 100 μg rPMY emulsified in
750 μg Quil A (Gerbu Biotechnik, Germany) as adjuvant
(rPMY group) at each vaccination. The adjuvant only-
control group received the same amount of adjuvant
mixed with 50 mM Tris buffer (pH 8.0) instead of the
antigen. The vaccine group of the second trial received
again 100 μg rPMY emulsified in 750 μg Quil A. As rPMY
contained a GST-tag at the N-terminus which might influ-
ence immunological reactions of the rPMY-vaccinated cat-
tle, a GST-control group was included in the second trial.
These calves received 100 μg “GST-tag” (Schistosoma
japonicum-GST), which was produced by expression of
the empty pET-41a expression vector. Again, Quil A was
used as adjuvant. The Dictol group, which served as a
positive control, was vaccinated with the Bovilis©Dictol
vaccine (Bovilis® Huskvac, MSD Animal Health, Ireland).
Accordingly, cattle were orally vaccinated on study day
14 and 42 with 25 ml larval suspension, each containing
1000–2000 viable D. viviparus third stage irradiated lar-
vae. All animals were weighed prior to first immunization
as well as necropsy to determine whether vaccination had
an influence on weight gain.
Challenge infection
On study days 62, 63, and 64 cattle were challenged by oral
application with each 1100 infective third stage larvae (total
of 3300 L3) of the D. viviparus isolate HannoverDv2000
in the first trial and with each 1000 L3 (total of 3000 L3)
in the second trial. The D. viviparus isolate was maintained
at the Institute for Parasitology, University of Veterinary
Medicine Hannover, Germany.
Determination of antibody development
During the first vaccine trial blood samples were taken
weekly beginning from study day 0 until necropsy onstudy days 98/99. During the second trial, blood samples
were available from day 0, 21, 42, 63 and 96 except the
Dictol vaccine group, which was sampled on study day
14 (first Dictol vaccination) instead of study days 0 and
21. Obtained serum samples were stored at −20°C until
analysis.
Antibody development against vaccinated rPMY was
determined by ELISAs analyzing immunoglobulin classes
IgM, IgA, IgE, whole IgG as well as the subclasses IgG1
and IgG2.
Nunc Amino Immobilizer 96 well plates (Thermo Scientific,
Germany) were coated with 100 μl/well of 2.5 μg/ml
rPMY dissolved in PBS by overnight incubation at 4°C.
Plates were washed three times using PBS containing 0.05%
Tween (PBST) before 100 μl of sera (diluted 1:40 in PBS
in the first vaccination trial and 1:10 in the second trial) in
LowCross Buffer® (CANDOR Bioscience, Germany; always
diluted 1:2 with distilled water) were added to each well.
For detection of IgE, sera were used undiluted. After one
hour incubation at 37°C the wells were washed three times
with PBST. Subsequently, 100 μl LowCross Buffer® con-
taining 10 ng (first vaccination trial) or 20 ng (second vac-
cination trial) secondary antibodies was added to each well
and incubated for 1 hour at 37°C. Secondary antibodies
were sheep anti-bovine IgA:horseradish peroxidase (HRP),
sheep anti-bovine IgG:HRP, sheep anti-bovine IgG1:HRP,
sheep anti-bovine IgG2:HRP and sheep anti-bovine IgM:
HRP (AbD Serotec, Germany). For IgE-detection, a mono-
clonal rat anti-bovine IgE antibody (5A2 IgG2a tissue
culture supernatant), directed against the recombinantly
expressed ε heavy chain constant region of bovine IgE was
developed, and used at a 1:40 dilution in LowCross Buffer®.
After 1 hour incubation at 37°C and three times washing
with PBST, 100 μl/well LowCross Buffer® containing 20 ng
HRP-conjugated mouse F(ab’)2 anti-rat IgG (H+ L) anti-
body (1 mg/ml; Jackson ImmunoResearch Laboratories,
USA) was added. Again, incubation conditions were 37°C
for 1 hour. After removal of the final antibody solution,
the wells were washed three times with PBST and wells
were filled with 50 μl o-phenylenediamine hydrochloride
(Sigma-Aldrich, Germany) dissolved in 25 mM citrate/
50 mM phosphate buffer containing 0.04% hydrogen per-
oxide. After ten minutes of incubation at room temperature
in the dark, the reaction was stopped by addition of 50 μl/
well 2.5 M sulfuric acid. Optical density (OD) was mea-
sured at a wavelength of 490 nm using the ELx800™
Absorbance Microplate Reader (BioTek, Germany). All
serum samples were analyzed as duplicates. For each set
of duplicates, the mean was calculated for data analysis.
Determination of shedding of larvae
Individual fecal samples were collected daily from study
day 84 to 97 during the first vaccination trial and on
study day 85, 89 and 92 during the second vaccination
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feces (second vaccination trial) were processed using the
Baerman technique followed by calculation of larvae
number per 1 g feces (LPG). LPG values of each animal
were summed and the overall arithmetic and geometric
means were calculated. For geometric mean calculation,
a logarithmic transformation (ln[count + 1]) was applied
to individual LPG values to address skewness of the
data, as well as zero counts. Back-transformed geometric
means were calculated by ex − 1, where x equals the
mean of logarithmically transformed values. Arithmetic
and geometric standard deviations (SD) were calculated.
Arithmetic SD (SDa) was calculated as the square root of
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In contrast to SDa, SDg is a multiplicative factor and
therefore dimensionless.
Reduction in larvae shedding based on arithmetic or
geometric means was calculated as follows:
Reduction %½  ¼ ð1−Mean larvae counts vaccinated group=
Mean larvae counts control groupÞ  100
Statistical analyses were done using t-test or Mann–
Whitney-Rank sum test if the data failed the normality
test (SigmaStat software, version 3.1, Systat Software,
Germany). A p-value ≤0.05 was considered statistically
significant.
Determination of worm burden and worm size
After necropsy on study days 98 and 99 (first trial) as
well as study days 96, 97 and 98 (second trial), lungs of
individual cattle were removed. To retrieve adult worms,
lungs were carefully dissected; the tracheoles, bronchi
and bronchioles were opened with scissors and all visible
parasites were taken out using tweezers. In the second
vaccination trial, lungs were additionally perfused via the
pulmonary artery. Worms were counted and additionally
separated by sexes in the first trial. In case of damaged
worms, only tails were counted and sexed. Reductions in
worm burden based on arithmetic and geometric means
as well as statistical analyses were calculated as de-
scribed above.
To estimate if the vaccine has an influence on adult
worm size, 25 male and 25 female worms per animal
were investigated by lengths and widths measurements.
If less than 25 worms per sex and cattle were collected,
all available worms per sex were measured. For this pur-
pose, worms were plated on a black pad and photo-
graphed. For subsequent size measurements cellB Basic
imaging software (version 3.1, Olympus Soft ImagingSolutions, Germany) was used. The overall group mean
worm length or width was calculated on basis of all individ-
ual worms belonging to the respective vaccination group.
Statistical analyses were performed as described above.
Immunohistochemical staining
Cryosections of adult D. viviparus in Leica Jung Tissue
freezing medium (Leica, Germany) were prepared using
the Cryotome Leica 2800E Frigocut Microtome Cryostat
(Leica, Germany). Longitudinal- and cross-cryosections
(10 μm thick) were produced, transferred to Superfrost™
plus slides (Thermo Scientific, Germany) and dried in a
desiccator for 48 hours. Ice cold (−20°C) acetone was added
for fixation [10 minutes at room temperature (RT)] and
slices were subsequently dried at RT and afterwards rinsed
with PBS. After carefully dabbing and encircling the tissue
with a DAKO-pen, a monoclonal anti-C. elegans-PMY
antibody (1.85 μg/ml; available under the designation 5–
23 from the Developmental Studies Hybridoma Bank,
USA) diluted 1:10 in PBS-5% goat serum was dripped on
the slides followed by 1 hour incubation at RT. Slides were
then rinsed two times with PBS and once with double dis-
tilled water. Goat anti-mouse IgG-FITC (1 mg/ml; AbD
Serotec, Germany) was used as secondary antibody in di-
luted 1:1000 in PBS (final concentration 5 μg/ml). Incuba-
tion was again 1 hour at RT in the dark, followed by two
times washing with PBS and once with double distilled
water before drying at RT. Afterwards, slices were covered
with 100 μl Mowiol including 1:200 diluted DAPI (1 μg/ml,
Sigma-Aldrich, Germany) as mounting medium and
allowed to dehydrate for approximately 24 hours in the
dark. Sections were visualized with a fluorescence micro-
scope (Nikon Eclipse Ti, Nikon, Germany) and photo-
graphed using the software NIS-elements AR 64 bit
(version 2.3, NIKON, Düsseldorf, Germany).
Results
Conditions of the calves
In the second trial, three animals (one of the GST-control
group, one of the rPMY group and one of the Dictol vac-
cine group) had to be euthanized before challenge infec-
tion due to severe weight loss and diarrhea independently
from treatment. Therefore, results include five cattle per
group only. Three animals of the GST-control group (ani-
mal ID 412, 361 and 553) had to be treated with antibi-
otics (Marbocyl©, Vétoquinol, WDT, Germany) for up
to 5 days and the remaining two animals of the group
had also to be treated with anti-inflammatory meloxicam
(Metacam©, Boehringer Ingelheim Vetmedica, Germany)
for 2 days. The Simmental calf (animal ID 553) did not re-
cover and had to be euthanized three days before the ini-
tially planned necropsy due to severe dictyocaulosis, but
was subjected to parasitological necropsy and results were
included in the study. Remaining cattle of the trials
Table 1 Vaccination parameters weight gain, larvae counts and worm burden
Animal ID Weight gain [kg] Larvae counts [LPG]* Total worm count Male worm count Female worm count
Trial 1
Adjuvant only-control group
110 59 1047 1136 447 689
795 58 569 798 324 474
802 62 53 213 77 136
805 60 302 453 159 294
808 66 304 433 142 291
814 59 153 651 260 391
Arithmetic mean 61.7 404.7 614.0 234.8 379.2
SDa 2.9 359.8 324.7 136.3 189.4
Geometric mean 60.6 276.7 539.7 200.9 337.9
SDg
** 1.0 2.8 1.7 1.8 1.7
rPMY group
806 69 609 925 351 574
812 49 131 4 1 3
813 76 7 64 21 43
822 70 116 126 60 66
Arithmetic mean 66.0 215.8 279.8 108.3 171.5
SDa 11.7 267.9 433.0 163.7 269.6
Geometric mean 65.1 92.2 77.6 30.2 50.0
SDg
** 1.2 5.0 7.0 8.5 6.5
Reduction [%]*** 46.7 (66.7) 54.4 (85.6) 53.9 (85.0) 54.8 (85.2)
Trial 2
GST-control group
361 22 67 940
129 n.a. 12 42
412 30 128 1101
269 53 84 873
553 18 201 1871
Arithmetic mean 30.8 98.4 965.4
SDa 15.6 70.8 652.0
Geometric mean 28.2 71.2 591.4
SDg
** 1.5 2.6 3.8
rPMY group
699 39 87 1019
485 56 73 1192
034 70 25 917
906 76 0 0
887 23 26 209
Arithmetic mean 52.8 42.2 667.4
SDa 21.9 36.4 528.4
Geometric mean 48.6 20.5 187.0
SDg
** 1.1 n.a. n.a.
Reduction [%]*** 57.1 (71.2) 30.9 (68.4)
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Table 1 Vaccination parameters weight gain, larvae counts and worm burden (Continued)
Dictol vaccine group
214 48 1 2
688 36 13 152
598 79 1 63
221 48 1 50
825 46 16 56
Arithmetic mean 51.4 6.4§ 64.6
SDa 16.2 7.5 54.4
Geometric mean 49.7 3.5 37.6
SDg
** 1.1 1.5 1.6
Reduction [%]*** 93.5 (95.0) 93.3 (93.6)
SDa = arithmetic standard deviation, SDg = geometric standard deviation, n.a. = not available.
*Values represent the sum of fecal larvae counts from day 84 to 97.
**SDg is a multiplicative factor and therefore dimensionless.
***Percent reduction based on arithmetic mean with values in brackets representing percent reduction based on geometric mean.
§p ≤ 0.05.
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tory sounds occasionally.
In the second trial, the average weight gain of cattle
(Table 1) belonging to the rPMY and Dictol group were
considerably higher than those of the GST-control group;
however, results were not statistically significant.
Parasitological parameters (larvae shedding, worm
burden and worm size)
Reduction of larvae shedding in rPMY-vaccinated cattle
based on arithmetic mean was 46.7% (geo. mean: 66.7%) in
the first and 57.1% (geo. mean: 71.2%) in the second vaccin-
ation trial. Arithmetic mean LPG of the Dictol vaccine
group was with 93.5% reduction of larvae shedding statisti-
cally significantly lower compared to the GST-control
group. Adult worm burden was reduced by 54.4% (geo.
mean: 85.6%) in rPMY-vaccinated animals of the first trial
and 30.9% (geo. mean: 68.4%) in the second trial. Reduction
of worm burden of the Dictol vaccine group was 93.3%
(geo. mean: 93.6%). Detailed data are listed in Table 1.
Adult lungworm measurements of the rPMY-vaccinated
cattle of the first trial showed significantly reduced worm
lengths, while widths were significantly enlarged. In the
second trial, worm lengths as well as widths of the rPMY-
vaccinated group were significantly smaller than those of
the GST-control group. The average length and width of
female worms of the Dictol vaccine group were signifi-
cantly smaller than those of the GST-control. This was
also true for the average width but not length of male
worms. Results of lungworm size measurements are sum-
marized in Table 2.
Determination of antibody response to vaccination
All rPMY-vaccinated animals developed antibodies in re-
sponse to vaccination. Most prominent immunoglobulin(sub)classes were IgG including IgG1 and IgA, whereas
no IgE response was detectable in the serum samples. The
latter also applies to all tested serum samples with excep-
tion of one GST-control group animal (ID 412) at study
day 98, at which a weak IgE increase was observed.
The GST-control animals of the second trial (but not
the adjuvant only-control of the first trial) developed anti-
bodies in response to vaccination as well, but with less
intensity compared to rPMY-vaccinated animals. Again,
most prominent immunoglobulin (sub)classes were IgG
including IgG1.
After challenge infection, no increase in antibody inten-
sity was detected within any of the groups, except of ani-
mal no. 808 (adjuvant only-control, trial 1), which showed
a distinct IgG and IgG1 increase and a slight IgA increase.
Furthermore, animal no. 805 (adjuvant only-control, trial 1)
showed increased IgM levels. Sera of the Dictol group did
not show any antibody response to rPMY. Determined
anti-PMY-antibody curves are shown in Figure 1 (first
vaccination trial) and Figure 2 (second vaccination trial).
Immunohistochemical staining
FITC-labeled antibodies directed against anti-C. elegans-
PMY antibodies reacted strongly with the pharyngeal
muscles and longitudinal somatic muscles of the body wall
(Figure 3). No staining was seen in the negative control
sections.
Discussion
The development of a recombinant subunit vaccine against
a helminth parasite would be a milestone in parasite con-
trol of livestock. This study intended to test the protective
potential of bovine lungworm-rPMY as a vaccine candi-
date and in both conducted trials, vaccination with rPMY
resulted with 54.4% (geo. mean: 85.6%) and 30.9% (geo.
Table 2 Worm size measurements
No. of worms counted Male worms No. of
worms counted
Female worms
Animal-ID Mean length [mm] Mean width [mm] Mean length [mm] Mean width [mm]
Trial 1
Adjuvant only-control group
110 25 40.32 0.43 25 55.47 0.47
795 25 36.71 0.41 25 47.17 0.43
802 25 29.90 0.30 25 40.56 0.34
805 25 34.02 0.37 25 47.99 0.44
808 25 35.38 0.38 25 46.07 0.41
814 25 35.39 0.35 25 46.46 0.41
Sum/overall mean 150 35.29 0.37 150 47.29 0.42
SD 4.64 0.06 6.59 0.06
rPMY group
806 25 38.21 0.49 25 51.08 0.52
812 1 29.97 0.43 3 40.55 0.48
813 12 29.45 0.39 18 36.65 0.43
822 25 31.72 0.46 24 41.57 0.46
Sum/overall mean 113 33.84* 0.46* 70 43.66* 0.49*
SD 4.93 0.08 7.64 0.08
Trial 2
GST-control group
361 25 31.71 0.33 25 39.89 0.40
129 11 26.03 0.28 25 32.63 0.34
412 25 32.95 0.35 25 49.25 0.45
269 25 34.82 0.36 25 46.04 0.40
553 25 32.74 0.35 25 44.30 0.40
Sum/overall mean 111 32.35 0.34 125 42.42 0.40
SD 3.91 0.05 7.11 0.07
rPMY group
699 24 28.55 0.27 25 38.37 0.28
485 25 33.23 0.30 25 40.56 0.36
034 25 29.66 0.29 25 39.88 0.37
906 0 - - 0 - -
887 25 28.32 0.33 25 35.30 0.37
Sum/overall mean 99 29.95* 0.30* 100 38.53* 0.34*
SD 3.11 0.05 4.44 0.06
Dictol vaccine group
214 0 - - 2 23.22 0.36
688 14 35.93 0.28 25 40.14 0.39
598 1 31.18 0.27 2 36.18 0.39
221 11 24.52 0.30 19 29.96 0.31
825 2 26.13 0.28 20 30.68 0.31
Sum/overall mean 28 30.58 0.29* 48 33.90* 0.34*
SD 6.59 0.03 6.45 0.07
SD = standard deviation.
*p ≤ 0.05.
























































































Adjuvant only-control 814 Adjuvant only-control 795 Adjuvant only-control 805 Adjuvant only-control 802
Adjuvant only-control 808 rPMY 812 rPMY 813 rPMY 806 rPMY 822
Figure 1 Anti-rPMY-antibody development during the first vaccination trial. Optical density (OD) values over time are for immunoglobulin
(Ig) classes IgG, IgG1, IgG2, IgM, IgA, IgM and IgE for the individual study animals. The graph legend lists animal IDs of each group.
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showing the protective capacity of rPMY. Several attempts
have been made to identify possible candidate proteins for
a recombinant subunit vaccine against D. viviparus
[23-26], but to date only one in vivo study in cattle has
been published using acetylcholinesterase as recombi-
nantly E. coli-expressed His-tagged protein combined with
Incomplete Freund’s adjuvant [27]. However, in contrastto the presented rPMY trials, acetylcholinesterase did not
lead to a reduced worm burden or larval shedding.
Compared to other trials with recombinant proteins
as vaccine candidates against cattle nematodes, e.g. the
polyprotein allergen (OPA) [28] or activation-associated
secreted proteins (ASPs) [29] of Ostertagia ostertagi, the
present study exhibits the highest level of protection of a




















































































rPMY 906 rPMY 699 rPMY 887 rPMY 485 rPMY 034 GST-control 361 GST-control 553 GST-control 129
GST-control 412 GST-control 269 Dictol 221 Dictol 214 Dictol 598 Dictol 688 Dictol 825
Figure 2 Anti-rPMY-antibody development during the second vaccination trial. Optical density (OD) values over time are for immunoglobulin
(Ig) classes IgG, IgG1, IgG2, IgM, IgA, IgM and IgE for the individual study animals. The graph legend lists animal IDs of each group.
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contortus resulted in a protection up to 95% regarding
worm burden and up to 99% regarding egg shedding by
use of native proteins like the gut membrane protein H11
and glycoprotein complex H-gal-GP as vaccine candidates
[30-33]. However, using the recombinant form of H11 as
antigen, only 30% reduced worm burden was observed
[34]. This and other studies [28,29] indicate that resultsachieved for isolated native proteins cannot be extrapo-
lated to recombinant proteins and results are not readily
comparable to those obtained with recombinant proteins.
The lower percentage reduction in worm burden of
rPMY-vaccinated cattle in the second trial might be ex-
plained by a change in the control group: While in the
first trial the control was vaccinated with the adjuvant in
Tris buffer only (adjuvant only-control group), the control
Figure 3 Localization of PMY in D. viviparus. Immunohistochemical staining localized PMY in the pharyngeal and body wall muscles of the
bovine lungworm. The long thick arrow indicates the pharynx, the short thick arrow the transition into the oesophagus. The thin arrow indicates
the cuticle and underlying body wall muscles.
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additionally recombinant GST fusion protein expressed
from the expression vector without PMY-insert (“empty
vector”). GST is known to induce an antibody response in
experimental animals [35] and moreover can induce a par-
tial protection against parasitic worms, including trema-
todes [36] as well as nematodes [37,38]. Hence, GST-
tagged proteins may increase the vaccination success,
which is why the GST-tag has not been removed from
rPMY prior to vaccination. It might be speculated that the
antibodies formed against the vector’s S. japonicum-GST
cross reacted with D. viviparus-GST - with the consequence
that the differences between the GST-control and rPMY
group became smaller in the second trial.
In addition to reductions in worm counts, it was ob-
served that worms of rPMY-vaccinated groups were sig-
nificantly shorter compared to those of the control groups,
independently of their sex. Since immunohistochemistry
showed that PMY is part of the bovine lungworm body
wall and pharyngeal muscles, it can be assumed that
vaccination-induced antibody development had an in-
fluence on the parasite’s development. Similar observa-
tions were made in flies, in which antibodies directed
against muscular elements passed through the gut and in-
terfered with function and growth of the muscular system
[39,40]. As early passive transfer studies using hyper-
immune sera revealed that antibodies play a major role
for the protective immunity against the bovine lung-
worm [41], antibody development against rPMY was ana-
lyzed. In both trials, rPMY-vaccinated animals showedimmunological reactions against the vaccine antigen. The
most distinct increases were observed for IgG and the
subclass IgG1 as well as IgA. These immunoglobulins are
secreted onto the bovine mucosa [42-44] and the observed
reductions in parasitological parameters might at least
partially be attributed to them. When comparing results
of rPMY receiving animals with the respective control
group (trial 1: adjuvant only-control group; trial 2: GST-
control group), antibody titers of adjuvant only-control
animals of the first trial remained more or less on the
same level as at the beginning of the trial. By contrast, IgG
as well as IgG1 and to a much lesser extend IgA titers of
the GST-control group increased in response to vaccin-
ation. It has to be noted, however, that these ELISA results
probably represent the reaction of developed anti-GST
antibodies with the GST-part of the coated PMY fusion
protein. The missing IgE-development against rPMY
could either be explained by the general lack of free IgE in
sera since it is bound to cell surfaces of e.g. basophilic
granulocytes, or a general lack of a specific IgE response
against rPMY. The lack of any Ig-increase in the Dictol-
control group as well as the lacking increase in all but
two study animals after challenge infection indicate that
PMY is a hidden antigen. A counter-argument to this
assumption is a possible unresponsiveness of antibodies
developed against rPMY to native PMY. However, im-
munohistochemistry results which demonstrated the
pharyngeal and longitudinal somatic muscles of the body
wall as PMY location strongly support the hidden antigen
hypothesis.
Strube et al. Parasites & Vectors  (2015) 8:119 Page 11 of 12In the present study most results achieved were not sta-
tistically significant, due to the high variance of results, es-
pecially those for worm burden and larvae counts. This
problem has already been described previously [41] and
becomes obvious in the lacking statistical significance of
93.3% (or 93.6% when considering the geometric mean)
reduction in worm burden regarding the Dictol vaccine
group. A substantial increase of group sizes could solve
the problem, but was not considered since the performed
vaccination trials represented pilot studies.
A general challenge regarding vaccination with recom-
binant D. viviparus-PMY might be the occurrence of amino
acid substitutions among three PMY transcript variants
[13]. Vaccination trials against F. hepatica with recombin-
ant fatty acid binding protein resulted in a reduced protec-
tion compared to the native protein fraction. The authors
explained this outcome by the occurrence of eight different
isoforms of the mentioned protein and that the one used
for the recombinant vaccine was probably less immuno-
genic [45]. In addition, there is the possibility that naturally
occurring isoforms are not recognized by antibodies formed
against a recombinant isoform when the difference is part
of the epitope. However, the observed 10 amino acids sub-
stitutions among the 876 deduced amino acids of bovine
lungworm PMY [13] should not affect binding of the ma-
jority of developed antibodies among PMY variants.
General approaches for improvement of vaccination
success could include a change of the expression system.
Since D. viviparus is an eukaryotic organism, an expres-
sion system capable of post-translational modifications
might deliver a rPMY which resembles the original more
closely. Prediction of N-glycosylation sites for D. viviparus-
PMY using the GlycoEP web server [46] resulted in a po-
tential N-glycosylation at amino acid position 653 (data
not shown). This could be of relevance since it has
been suggested that D. viviparus-proteins carry immune
dominant N-glycan moieties which influence the immune
response during infection as well as after live vaccination
[47]. Nevertheless, the ultimate goal of vaccinations against
nematodes is not necessarily a complete prevention of
the establishment of worms, but the prevention of health
problems, avoidance of economic losses and at the same
time the possibility for the development of a stable im-
munity by natural booster infections. According to Barnes
et al. [48], a substantial vaccination benefit against gastro-
intestinal worm infection of sheep can be achieved already
when the vaccine protects about 80% of the flock with an
efficiency of 60%. Whether or not these values can also be
applied for the bovine lungworm needs to be evaluated in
appropriate studies including model calculations.
Conclusions
The vaccine antigen rPMY partially protected cattle
against D. viviparus infection, although the live vaccineBovilis©Dictol induced a higher reduction in worm bur-
den and shedding of larvae. Furthermore, rPMY revealed
significant shorter worms after challenge infection be-
sides reduction of worm burden and larvae shedding. In
all, achieved reductions in worm burden, worm size and
shedding of larvae make rPMY a promising candidate for
further vaccination studies offering multiple possibilities
for further improvements. Such improvements might be
an eukaryotic expression system or the replacement of the
adjuvant, since many different parameters of the immune
response are influenced by the adjuvant and the vaccin-
ation success can be heavily influenced by their choice
[49]. Furthermore, combinations of different recombinant
D. viviparus proteins may also have an additive or syner-
gistic effect.
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